A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2004
12/28/2004	US6835546 Drosophila G protein coupled receptors, nucleic acids, and methods related to the same
12/28/2004	US6835384 Nucleic acids and polypeptides specific of the neisseria genus pathogenic strains
12/28/2004	US6835372 Mixtures of di-(tri)peptides and drugs such as cyclosporin used as aerosols; drug delivery
12/28/2004	US6835370 Diagnosis and treatment of malignant neoplasms
12/26/2004	CA2458893A1 Treatment of chronic human viral hepatitis
12/23/2004	WO2004111608A2 Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
12/23/2004	WO2004111270A2 Differential gene expression in schizophrenia
12/23/2004	WO2004111250A1 Recombinant adeno-associated virus vector for treatment of alzheimer disease
12/23/2004	WO2004111249A2 Protein constructs containing caspase recognition sites
12/23/2004	WO2004111087A2 Chemokin-binding protein thap1, methods and use thereof
12/23/2004	WO2004111081A2 Antigenic peptides of sars coronavirus and uses thereof
12/23/2004	WO2004111080A1 Epitopes of the cytomegalovirus pp65 protein
12/23/2004	WO2004111075A2 Alternative reading frame polypeptides for treatment
12/23/2004	WO2004110980A1 Sphingolipids' polyalkylamines conjugates
12/23/2004	WO2004110499A1 Sphingolipids polyalkylamine conjugates for use in transfection
12/23/2004	WO2004110496A1 Sphingoid polyalkylamine conjugates for vaccination
12/23/2004	WO2004110487A1 Treatment of t cell mediated diseases by inhibition of fgfr3
12/23/2004	WO2004110486A1 Functionally reconstituted viral membranes containing adjuvant
12/23/2004	WO2004110485A1 Materials and methods for improved vaccination
12/23/2004	WO2004110484A1 Method for producing a live tissue-cultural vaccine against influenza virus
12/23/2004	WO2004110483A1 Method and composition of a novel vaccine design for the prevention and treatment of sars
12/23/2004	WO2004110482A1 Improved vaccines
12/23/2004	WO2004110481A2 Listeria attenuated for entry into non-phagocytic cells, vaccines comprising the listeria, and methods of use thereof
12/23/2004	WO2004110480A2 Polyanionic polymer adjuvants for haemophilus influenza b saccharide vaccines
12/23/2004	WO2004110392A2 Compositions and methods for treating coronavirus infection and sars
12/23/2004	WO2004110390A2 Anti-cd74 immunoconjugates and methods
12/23/2004	WO2004110384A2 Hiv-1 envelope glycoproteins having unusual disulfide structure
12/23/2004	WO2004110373A2 Therapeutic vaccine compositions for the treatment of type 1 diabetes
12/23/2004	WO2004110370A2 Etiologic agnet for sow infertility syndrome
12/23/2004	WO2004110367A2 Sdr proteins from staphylococcus capitis and their use in preventing and treating infections
12/23/2004	WO2004110363A2 Method of inhibiting tumor growth with anti-tissue factor antibodies
12/23/2004	WO2004110356A2 Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
12/23/2004	WO2004110349A2 Sars t cell epitopes and methods for identifying same
12/23/2004	WO2004110345A2 Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
12/23/2004	WO2004110250A2 Diagnostic method for atherosclerosis
12/23/2004	WO2004093904A3 Modified live vaccines comprising bhv-1(ibr) and/or bvdv pregnant and nursing cattles
12/23/2004	WO2004087864A3 Amended recombinant cells (arcs) for the production and delivery of antiviral agents, adjuvants and vaccine accelerants
12/23/2004	WO2004087204A3 Microfluidized oil-in-water emulsions and vaccine compositions
12/23/2004	WO2004087203A3 Immunostimulatory nucleic acid oil-in-water formulations for topical application
12/23/2004	WO2004083251A3 Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
12/23/2004	WO2004074310A8 Mycobacterial diagnostics
12/23/2004	WO2004072263A3 Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
12/23/2004	WO2004067706A3 Production of multimeric proteins
12/23/2004	WO2004045499A3 Identification of actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases
12/23/2004	WO2004024182A3 Method for isolating hepatitis c virus peptides
12/23/2004	WO2003106692A3 Methods for the identification of all-antigens and their use for cancer therapy and transplantation
12/23/2004	WO2003106634A3 Vectors for expression of hml-2 polypeptides
12/23/2004	WO2003089002A9 Fp receptor antagonists or pgf2 alpha antagonists for treating menorrhagia
12/23/2004	WO2003076569A3 Novel polypeptides having sequence similarity to gdnfr and nucleic acids encoding the same
12/23/2004	US20040260069 Modified anti-tnf aplha antibody
12/23/2004	US20040260061 Continuous, normal human t-lymphocyte cell lines comprising a recombinant immune receptor with defined antigen specificity
12/23/2004	US20040259838 Staphylococcus aureus exopolysaccharide and process
12/23/2004	US20040259829 Carboxylesterase; antitumor agents; drug screening; bioassay
12/23/2004	US20040259825 Gene expression vectors; intensifier dor sequence determiantion; induce immunology response; viricides
12/23/2004	US20040259822 Antibody which recognizes epitope containing nucleic acid coupled to active protein; hybridomas
12/23/2004	US20040259797 peptide mixture; induce immunology response; gag protein; vaccines
12/23/2004	US20040259781 Drug screening ; polypeptide interfers with binding of fibronectin to; anticancer agents; antihistamines, antiarthritic agents, autoimmune disease, wound healing agents
12/23/2004	US20040259767 Antiproliferative agents; therapy for human progessive leukoencephalophy ; suppression of dna viruses; anticancer agents
12/23/2004	US20040259225 Virulent systemic feline calicivirus
12/23/2004	US20040259224 prevent or to treat Dengue infection; inducing an immune response to the four serotypes of dengue virus using a vaccine comprising four chimera comprising the capsid and non-structural proteins of Yellow Fever virus and the pre-membrane and envelope proteins of Dengue-1,-2,-3, and -4 virus types
12/23/2004	US20040259150 Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa
12/23/2004	US20040259139 Novel proteins in enteroaggregative escherichia coli (EAEC) useful for diagnosis and therapy of EAEC infections
12/23/2004	US20040259126 MN gene and protein
12/23/2004	US20040259110 Gene PRV-1 and its use
12/23/2004	US20040259084 Diagnostic and therapeutic methods based on the l1 adhesion molecule for ovarian and endometrial tumors
12/23/2004	US20040259077 Administering antibodies, heavy/light chains, and FAB fragments to treat anaphylactic hypersensitivity, bee stings, snake bites, asthma, allergic rhinitis, eczema, urticaria and food allergies; point mutations
12/23/2004	US20040258770 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine, a platinum compound, an antineoplastic antimetabolic agent and folinic acid; colorectal cancer
12/23/2004	US20040258763 Methods of manufacture and use of calcium phosphate particles containing allergens
12/23/2004	US20040258746 Freeze dried liposomes having antigen and of different sizes before lyophilization; orally administering to mammal; absorption in Peyer's patches of gut and taken up by macrophages; viral, fungal, and bacterial antigens; vaccines
12/23/2004	US20040258715 Porcine circoviruses, vaccines and diagnostic reagents
12/23/2004	US20040258714 Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
12/23/2004	US20040258713 Attenuated mutant newcastle disease virus strains for in ovo vaccination, method for preparing and their use
12/23/2004	US20040258709 Hepatitis B virus polypeptides
12/23/2004	US20040258708 Cytotoxic T-cell epitopes of papillomavirus L1 protein and their use in diagnostics and therapy
12/23/2004	US20040258707 Nucleotide sequences encoding the structural proteins (causative agent) which consists of a basic capsid protein, three envelope proteins designated as E1, E2 and E3, and a 6K protein; stable DNA vaccines and vector vaccines of live attenuated modified bacteria or virus; kits for medical diagnosis
12/23/2004	US20040258705 Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
12/23/2004	US20040258704 Bovine lactation associated immunotropic protein (CD14), encoding gene and application in B cell activation
12/23/2004	US20040258703 Skin-active adjuvants for transcutaneous immunization
12/23/2004	US20040258702 Immunogen formulation comprising antigen, biocompatible polymer and liquid vehicle for stimulation of an immune response; the polymer interacts with the liquid vehicle to impart reverse thermal viscosity behavior to the composition, i.e. reverse thermal gelation; potentiation
12/23/2004	US20040258701 Potentiation of the immunogenicity of animal vaccines using an adjuvant of light hydrocarbon non-metabolizable oil, surfactant, and an aqueous component; mean oil droplet size is <1 mu m.; antigens intrinsically or extrinsically combined; immunostimulants; stability; nontoxic; veterinary medicine
12/23/2004	US20040258700 A nontoxic mixture of 2-phenoxyethanol and para hydroxybenzoates, (e.g. methyl-, ethyl-, propyl- or butyl-, p-hydroxybenzoate) more effective than 2-phenoxyethanol alone (mixture, called TF-1); effect comparable to that of thiomersal or chloroform in vaccines
12/23/2004	US20040258698 Delivery of immune response modifier compounds
12/23/2004	US20040258697 Methods of using multivalent MHC class II-peptide chimeras
12/23/2004	US20040258695 Transferrin binding peptides and uses thereof
12/23/2004	US20040258693 Customization of cancer therapy by adminstering modifying antibodies from antigens expressed from cancerous tissue which are cytotoxic to cancer cells while non-toxic to non-cancerous cells; monoclonal antibody antigen binding fragment having identifying characteristics to deposit PTA-4890 at the ATCC
12/23/2004	US20040258692 Method for the treatment of cardiotoxicity induced by antitumor compounds
12/23/2004	US20040258691 Treating psoriasis in a patient by administering a therapeutically effective amount of an antibody immunospecific for vetronectin receptor av beta 3; antiinflammatory agents; antibody does not immunoreact with integrins other than av beta 3; cell adhesion
12/23/2004	US20040258689 Augmenting activin induced signaling in cells; screening for complex inhibitors; treatment of reproductive, developmental, skin, bone, hepatic, hematopoietic and/or central nervous system disorders; prostrate cancer
12/23/2004	US20040258688 Long lasting immunity using single dose at low concentration; exposing dendritic cells to antigen-antibody-DEC-205 receptor conjugate or to recombinant anti-DEC-205 antibody and promoting maturation
12/23/2004	US20040258687 Use of GCC ligands
12/23/2004	US20040258682 Monoclonal antibody or fragment engineered in non-Fc constant heavy or light region; immunoconjugates for cancer diagnosis and therapy
12/23/2004	US20040258680 Methos of healing or preventing inflammation, damage and other changes that occur prior to, during or immediately after a myocardial event with thymosin beta 4, analogoues, isoforms and other derivatives
12/23/2004	US20040258678 Isolated nucleic acid having high identity to sequence 215; vectors, host cells, antibodies
12/23/2004	US20040258672 Graft acceptance through manipulation of thymic regeneration
12/23/2004	US20040258661 Generation of use of tc1 and tc2 cells
12/23/2004	US20040258660 Tumor necrosis factor alpha analogues having three dimensional structure of similar to proteins from which they are derived; facilitating correct folding
12/23/2004	US20040258616 Compositions and methods for treating cancer using IGSF9 and LIV-1
12/23/2004	CA2529814A1 Chemokine-binding protein thap1, methods and use thereof
12/23/2004	CA2529496A1 Anti-cd74 immunoconjugates and methods
12/23/2004	CA2528402A1 Sphingoid polyalkylamine conjugates for vaccination

1 ... 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 ... 1823